Related references
Note: Only part of the references are listed.Polypill strategy at the heart of cardiovascular secondary prevention
Borja Ibanez et al.
HEART (2019)
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
Eri T. Kato et al.
CIRCULATION (2019)
Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus Results From the CANVAS Program
Gemma A. Figtree et al.
CIRCULATION (2019)
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)
John J. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics
John J. V. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
Gholamreza Roshandel et al.
LANCET (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Polypill for Cardiovascular Disease Prevention in an Underserved Population
Daniel Munoz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors
Cezary Wojcik et al.
CURRENT CARDIOLOGY REPORTS (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Triple-combination therapy in the treatment of hypertension: a review of the evidence
R. Duesing et al.
JOURNAL OF HUMAN HYPERTENSION (2017)
Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
James L. Januzzi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances
John J. V. McMurray
EUROPEAN JOURNAL OF HEART FAILURE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
Faiez Zannad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Karl Swedberg et al.
LANCET (2010)
Share Paper
